Literature DB >> 6279523

Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.

I Braveny, K Machka, R Elsser.   

Abstract

The in vitro activity of N-formimidoyl thienamycin (MK 0787), a new stable derivative of thienamycin was compared with that of lamoxactam, cefotaxime, cefoperazone, piperacillin and gentamicin against 410 clinical isolates of common bacteria. In comparison with the other agents, MK 0787 was more or equally active against Staphylococcus aureus, Streptococcus faecalis, Escherichia coli, Citrobacter spp., Klebsiella spp., and Serratia spp. It inhibited all isolates at a concentration of 0.5 mg/l, but was less active than cefotaxime and lamoxactam against Proteus mirabilis and less active than cefotaxime, lamoxactam and cefoperazone against Beta-lactamase positive Haemophilus influenzae. Strains of Pseudomonas aeruginosa were more susceptible to N-formimidoyl thienamycin than to other antibiotics.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6279523     DOI: 10.1007/bf01640838

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  7 in total

1.  N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; N Patel
Journal:  J Antimicrob Chemother       Date:  1981-05       Impact factor: 5.790

2.  Binding of thienamycin and clavulanic acid to the penicillin-binding proteins of Escherichia coli K-12.

Authors:  B G Spratt; V Jobanputra; W Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  1977-09       Impact factor: 5.191

3.  [Antibacterial activity of cefotaxim in comparison with seven cephalosporins].

Authors:  I Braveny; H Dickert; K Machka
Journal:  Infection       Date:  1979       Impact factor: 3.553

4.  MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.

Authors:  H Kropp; J G Sundelof; J S Kahan; F M Kahan; J Birnbaum
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

5.  In vitro activity of N-formimidoyl thienamycin (MK0787).

Authors:  F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

6.  In vitro activity of N-formimidoyl thienamycin (MK0787), a crystalline derivative of thienamycin.

Authors:  V W Horadam; J D Smilack; C L Montgomery; J Werringloer
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

7.  Antibacterial activities of a new stabilized thienamycin, N-formimidoyl thienamycin, in comparison with other antibiotics.

Authors:  T Kesado; T Hashizume; Y Asahi
Journal:  Antimicrob Agents Chemother       Date:  1980-06       Impact factor: 5.191

  7 in total
  7 in total

1.  [Clinical experience with imipenem/cilastatin in the treatment of severe infections in general surgery].

Authors:  M Mayer; J Brand; D Schlenkhoff; W Opferkuch
Journal:  Infection       Date:  1986       Impact factor: 3.553

2.  Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.

Authors:  M Mayer; C Tophof; W Opferkuch
Journal:  Infection       Date:  1988 Jul-Aug       Impact factor: 3.553

Review 3.  In vitro activity of imipenem--a review.

Authors:  I Braveny
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

4.  [Effect and tolerance of daily 2 X 1 g imipenem/cilastatin in general surgery].

Authors:  M Wenzel; H Loch
Journal:  Infection       Date:  1986       Impact factor: 3.553

5.  [Bone concentrations of imipenem after a dose of imipenem/cilastatin].

Authors:  D H Wittmann; T H Kuipers; R Fock; M Höll; A Bauernfeind
Journal:  Infection       Date:  1986       Impact factor: 3.553

Review 6.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

Review 7.  Cefotaxime. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-03       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.